Junshi Biosciences & LEO Pharma Collaborate to Commercialize Toripalimab in Europe
Shots:
- Junshi with its subsidiary, TopAlliance, has partnered with LEO to market toripalimab in 32 EU countries incl. EEA, Switzerland & the UK. TopAlliance will remain the authorization holder overseeing development, manufacturing, registration & other activities in the EU
- LEO Pharma will handle the drug distribution, promotion & sales plus will pay an upfront & milestones on pursuing any subsequently approved indications as well as share double-digit percentage of net sales revenue
- Toripalimab (PD-1-targeting mAb) is approved by the EC & MHRA as a 1L treatment with cisplatin & gemcitabine for advanced/metastatic NPC as well as with cisplatin & paclitaxel for advanced/metastatic ESCC. BLAs are under review in countries like Singapore
Ref: Globenewswire | Image: Junshi Biosciences & LEO Pharma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
